Protest at housing association in King's Cross after baby death
Akram's mother, Aiat Mohammed, described her son as a "happy, playful baby". His father, Abdushafi, says he hoped for him to become a doctor. In late February, their baby son started struggling to breathe. His father took him in his arms and ran to hospital. Mrs Mohammed said: "I was trying to tell myself everything is going to be OK. I was trying to calm myself."There were more than eight doctors and more than five nurses around him."Akram's parents believe "longstanding mould and damp" in their flat contributed to their son's death. Akram's father said: "The house was mouldy and damp and I tried to explain to them many times but nobody helped."The coroner has yet to conclude the cause of death.
Paperwork seen by the BBC shows repeated requests from the family, and the charity the Pillion Trust, to address damp and mould in the flat.After the family launched a complaint in 2024 to the housing association, Notting Hill Genesis admitted their "standards have fallen for not being more responsive" and offered £175 in compensation for a late response, lack of communication and for being chased on damp and mould repairs.Photos taken by the family's legal team a week after Akram's death show mould and damp present in the one-bedroom home. Mrs Mohammed said Akram struggled with the conditions."If they just fixed those issues maybe he had a chance to live," she said."When he was just months old I started to notice he had difficulty breathing. He could (would) breathe very, very loudly. But eventually the problems got bigger and bigger."She added: "Nobody would stay there. Even for a minute. You couldn't breathe there. You would feel it in the air. The air was mouldy."
The family lawyer Mark McGhee said they have been told by the coroner's officer the pathology report stated the medical cause of death was acute pneumonia due to a late-onset Group B Strep infection and dilated cardiomyopathy, a type of heart muscle disease. The BBC has not independently seen the document. Akram's mother said: "We all know a person with pneumonia can't live in a mouldy house."The family's solicitors launched a disrepair claim against Notting Hill Genesis, and an independent survey of the flat, carried out by TLB Services found the housing association failed in its duty to ensure the property was "fit for human habitation".It found mould in every room and "defective" extractor fans in the kitchen and bathroom were "causing excessive airborne moisture".The survey advised £3,055 of repairs to be carried out, including washing the mould and fixing the extractor fans.Notting Hill Genesis said they conducted a thorough mould wash following reports of damp and mould in April 2024, which removed mould from the home.It added, in October 2024, the month prior to Akram's birth, Mr and Mrs Mohammed reported further issues of damp and mould, which the housing association was working to resolve.
Mrs Mohammed said: "I would say my baby's death was avoidable."All we wanted was a healthy environment to live [in]."Akram's parents said they have been supported by the school, of their two other children, and charities since their son's death.Mr Franco, the chief executive of Notting Hill Genesis, added: "We are deeply saddened by the tragic loss of Akram Mohammed. "We will continue to support the family in any way we can during this difficult time."No determination has been made by HM Coroner as to the cause of Akram's death, and it would therefore be inappropriate to comment further or to speculate at this time."A Camden Council spokesperson said: "Akram's death is a tragedy and our thoughts are with his family at what is a very sad time. "We have been in regular contact with Notting Hill Genesis who assure us they are working to identify a suitable home for the family."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
24 minutes ago
- Daily Mail
How to switch from Mounjaro to Wegovy WITHOUT risking weight gain, reveals top GP - as 'King Kong' jab is set to TRIPLE in price
A leading GP has issued guidance to patients on how to safely switch between weight loss drugs—as prices of the popular jab Mounjaro are set to soar. Dr Donald Grant, GP and Senior Clinical Advisor at The Independent Pharmacy, warned it is 'crucial' to transition under medical supervision in order to limit severe side effects and weight gain. His statement comes as CheqUp, one of the UK's largest providers of weight-loss treatments, reports sales of rival treatment Wegovy have jumped by more than 500 per cent in recent days as patients seek alternatives. Dr Donald Grant, GP and Senior Clinical Advisor at The Independent Pharmacy, said: 'As people consider potentially swapping Mounjaro for Wegovy, it's essential to understand the safe ways of transitioning between these two treatments. 'This can limit drastic side effects and avoid progress from plateauing.' 'It's crucial for people on these treatments to maintain open and honest conversations with their prescribing clinician or GP, who can provide tailored advice based on medical history and prior doses. 'You can't make a direct 'mg-for-mg' switch between Mounjaro and Wegovy because they are different drugs with different strengths. 'Instead, a medical professional will take a dose conversion approach, and if you make the decision to move, they will support you through this.' Mounjaro price increases Mounjaro®▼ (tirzepatide) KwikPen® Dose Current UK List Price New UK List Price (From September) 2.5mg £92 £133 5mg £92 £180 7.5mg £107 £255 10mg £107 £255 12.5mg £122 £330 15mg £122 £330 Earlier this month, Eli Lilly confirmed that the price of its blockbuster weight-loss jab Mounjaro will rise steeply for British patients from September 1. The drug, which is prescribed to around 90 per cent of people in the UK using weight-loss injections, will see the cost of its highest dose, 15mg, soar from £122 to £330 a month—a 170 per cent increase. Even mid-range doses such as the 5mg pen will jump from about £92 to £180, with an average rise across the range of 126 per cent. In the UK private market, Wegovy is generally cheaper. A 2.4 mg maintenance dose of Wegovy costs around £250 to £300 per month. At the lower end, Wegovy's starter dose is priced around £120 to £170. In clinical trials, Mounjaro has been shown to deliver the greatest weight loss of any licensed drug, with patients losing on average up to 22.5 per cent of their body weight over 72 weeks at the highest dose. By comparison, Wegovy patients lose up to 17.5 per cent over the same period on the full 2.4mg dose. Toby Nicol, CEO at CheqUp, said: 'As news of the Mounjaro price rise spreads, weight loss jab patients are voting with their wallets and making the switch to Wegovy, which is nearly as effective but has a considerably lower cost. 'We've been blown away by the huge spike in demand for Wegovy. It is too early to say for sure, but Wegovy will probably become the most popular weight loss treatment in the UK as patients switch from Mounjaro.' Superintendent Pharmacist Aaron Arman also stressed the importance of proper medical oversight: 'Both Mounjaro and Wegovy work in similar ways and are proven to be highly effective. 'For patients unable to afford the increase in price, it is possible to switch from Mounjaro to Wegovy, though the dose they can switch to will depend on the Mounjaro dose they are currently on.' CheqUp's research found as many as 80 per cent of current Mounjaro users will either switch or come off the drug entirely—an estimated 625,000 patients—while more than 325,000 say they have been priced out of treatment. Nicol added: 'A huge number of people will be considering switching and it's important they know that while this is absolutely possible, doing so under the supervision of a trusted pharmacist is a must. 'Simply stopping one treatment and moving to the other without due care can have serious health consequences.' Concerns are also mounting that so-called 'cowboy' operators will exploit the situation. Nicol warned: 'Black markets are going to try and exploit this situation. 'Go on any social media site and you can find cowboy operators in minutes—drug dealers, for all intents and purposes—taking advantage of confused patients who can no longer afford treatment but want to continue. As with most things in life, if it's too good to be true, it probably is.'
BBC News
2 hours ago
- BBC News
Palestine: Injured children could come to NI for treatment
Stormont's first and deputy first ministers are "close" to an agreement on allowing urgent medical treatment for children from Gaza as part of a UK-wide is understood that Michelle O'Neill and Emma Little-Pengelly are finalising plans by way of "urgent procedure" to enable Northern Ireland's participation in the scheme.A Stormont source told BBC News NI that a "very modest number" of children - possibly two or three - would be brought to NI under the medical could be among a group of between 30 and 50 critically ill and injured Palestinian children who are expected to be evacuated from Gaza to the UK for medical treatment in the coming weeks. The story was first reported in the Irish Minister Mike Nesbitt had previously expressed his support for the urgent procedure mechanism would mean the plan is not required to go to the whole executive for Executive Office and the Department of Health have both been contacted for comment.
Times
13 hours ago
- Times
‘Functional beverages' are booming — but is it all hype?
Before you take that magnesium supplement or sit down to meditate, what if a drink could help you relax? Enter 'functional beverages', drinks that claim to possess additional health benefits beyond those of a standard fizzy drink or fruit juice. Functional drinks are surging in popularity, with supermarkets in Britain seeing sales increase by 24.5 per cent in the past year, according to Worldpanel by Numerator. The market research firm also said that almost 30 per cent of UK households now purchase functional drinks. However, Nichola Ludlam-Raine, a dietician with more than 15 years of clinical experience in the NHS, has warned that she 'wouldn't rely on them [functional drinks] for measurable health benefits'. Ludlam-Raine, who now works privately and is the author of How Not to Eat Ultra-Processed , said: 'Functional drinks containing ingredients like CBD [cannabidiol], lion's mane [a type of mushroom], and ashwagandha [a herb typically used in ayurvedic medicine] are part of a growing wellness trend, but the science isn't as strong as the marketing.'
